Skip to main content

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Belen Perez Dueñas
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Clara Carnicer Cáceres, Mireia del Toro Riera, Ana Felipe Rucián
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Neurodegeneración en la cirrosis hepática: relación con el metabolismo nitrogenado y la inflamación

IP: -
Collaborators: José Antonio Arranz Amo, Xavier Nuvials Casals, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 215544.56
Reference: PI11/00954
Duration: 01/01/2012 - 31/03/2016

Efectos de la administración de fenilacetato y ornitina en pacientes con cirrosis hepática que presentan una hemorragia digestiva

IP: -
Collaborators: José Antonio Arranz Amo, Pilar Suñe Martin
Funding agency: Ministerio Sanidad
Funding: 43962
Reference: TRA-190
Duration: 01/01/2010 - 31/12/2012

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Santos Ortega, Alba

Santos Ortega, Alba

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Cañas Perea

Xavier Cañas Perea

Director/a d'Àrea
Clinical Research Development Directorate
Read more
Ruiz Esteve, Fernando

Ruiz Esteve, Fernando

Research technician
Neurovascular Diseases
Read more
Raul Juntas Morales

Raul Juntas Morales

Head of group
Peripheral Nervous System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.